Therapeutic Hypothermia Systems Market to Gain Momentum with Rising Cardiac Arrest Cases

The global therapeutic hypothermia systems market is projected to witness significant expansion over the next decade, driven by rising incidences of cardiovascular and neurological disorders, growing surgical procedures, and advancements in medical cooling technologies. Estimated at a market value of US$ 326.41 million in 2025, the market is expected to reach US$ 482.43 million by 2032, growing at a compound annual growth rate (CAGR) of 5.7% between 2025 and 2032.

Understanding Therapeutic Hypothermia Systems

Therapeutic hypothermia (TH), also referred to as targeted temperature management or induced hypothermia, is a critical medical technique aimed at lowering the body temperature to protect brain function and prevent tissue damage after neurological or cardiovascular trauma. It is widely used in patients recovering from cardiac arrest, traumatic brain injury, ischemic stroke, and neonatal hypoxic-ischemic encephalopathy (HIE). TH systems are broadly categorized into surface cooling systems—such as pads, blankets, and ice packs—and invasive cooling systems, such as endovascular cooling catheters.

Key Market Drivers

The increasing prevalence of cardiac arrests, myocardial infarctions, and strokes are pivotal growth drivers for the TH systems market. According to the World Health Organization, cardiovascular diseases remain the leading cause of global deaths, prompting the need for advanced critical care solutions. Over 310 million surgical procedures take place globally each year, making intraoperative temperature control crucial for improving surgical outcomes and minimizing postoperative complications.

Minimally invasive hypothermia systems with features like closed-loop feedback control, real-time temperature monitoring, and AI-enabled cooling algorithms are facilitating broader adoption across hospitals and intensive care units (ICUs). These systems significantly reduce risks such as bleeding, infection, and prolonged recovery periods, thereby enhancing patient outcomes and shortening hospital stays.

Restraints Hindering Market Growth

Despite the numerous clinical benefits, therapeutic hypothermia systems face certain challenges. The high cost of equipment and implementation remains a major barrier, particularly in low-resource healthcare settings. Many TH systems require specialized training and multidisciplinary teams to operate effectively, increasing operational costs.

Additionally, side effects such as shivering, electrolyte imbalances, bradycardia, and a higher risk of infection—especially pneumonia and bloodstream infections—limit widespread application. Hypothermia can also suppress immune function and affect drug metabolism, requiring careful patient monitoring.

Opportunities in Emerging Economies

Emerging markets are anticipated to offer lucrative opportunities for TH system manufacturers. High birth rates and increased incidences of neonatal HIE in countries across Asia, Africa, and Latin America are creating demand for affordable hypothermia technologies. Innovations such as India’s MiraCradle, a power-free, phase-change material-based cooling device, exemplify the successful adaptation of TH systems in resource-limited settings.

Public-private partnerships, global health NGO initiatives, and international collaborations like the Global South Alliance are accelerating access to life-saving TH treatments. These programs focus on training, infrastructure development, and contextual clinical research to support the deployment of hypothermia systems in underserved regions.

Segmental Analysis: Product Types

By product type, cooling devices are projected to dominate the market in 2025, accounting for around 60% market share. These devices include surface cooling pads, circulating water-based blankets, and cooling helmets. Their ease of use, lower cost, and compatibility with various clinical settings make them a preferred choice.

Meanwhile, cooling catheters are expected to be the fastest-growing segment. These invasive systems offer precise core temperature control, especially beneficial in emergency and post-operative critical care. Endovascular catheters that circulate chilled fluids through central veins are gaining popularity in advanced ICUs due to their efficiency in temperature management and ability to concurrently deliver medications.

Segmental Analysis: Indications

The neurology segment is poised to hold the largest share in 2025, driven by a growing prevalence of neurological emergencies such as ischemic stroke and traumatic brain injury. Studies have consistently demonstrated that TH can significantly reduce neuronal damage and improve recovery in such patients.

On the other hand, the cardiology segment is expected to witness the fastest growth during the forecast period. With around 640 million people worldwide living with heart and circulatory conditions, TH is becoming increasingly integrated into emergency response protocols for out-of-hospital cardiac arrests. Its proven ability to improve survival and neurological outcomes is making it indispensable in cardiology departments.

Regional Market Trends

North America is projected to lead the global therapeutic hypothermia systems market in 2025, holding approximately 45% of the total market share. The region’s dominance is supported by high disease prevalence, sophisticated healthcare infrastructure, and rapid adoption of advanced technologies. The United States, with nearly 795,000 strokes and 356,000 cardiac arrests annually, sees significant demand for TH interventions. Key players such as Medtronic, Stryker, ZOLL Medical, and Philips Healthcare maintain strong presence and continuously invest in R&D.

Asia Pacific is witnessing rapid growth, particularly in China and India. Factors such as rising cases of ischemic heart disease and stroke, increased healthcare spending, and government support for neonatal care programs are spurring the adoption of cooling devices. India’s REVIVE system by Sensivision Health Technologies stands out as an AI-integrated, servo-controlled neonatal TH device designed for low-resource settings.

China’s expanding healthcare capacity, exemplified by the growth in Class III hospitals from 2,200 in 2018 to over 2,800 in 2023, is enabling the wider rollout of therapeutic hypothermia systems. Integration of AI and remote monitoring technologies is further boosting market penetration.

Europe also presents promising growth, supported by a strong emphasis on neurological care and the presence of a geriatric population susceptible to strokes and cardiac conditions. Countries such as Germany and the UK have institutionalized TH in clinical guidelines. The Institute for Quality and Efficiency in Health Care (IQWiG) in Germany endorses therapeutic hypothermia for post-cardiac arrest care, while the UK’s NICE has recommended it for adults with shockable rhythm cardiac arrest.

European innovation is bolstered by funding under Horizon Europe, promoting research into next-generation hypothermia systems featuring real-time brain monitoring, precision cooling, and integrated diagnostics.

Competitive Landscape and Strategic Developments

The global therapeutic hypothermia systems market is marked by intense competition and continuous innovation. Leading players such as ZOLL Medical (Asahi Kasei), Medtronic, Becton Dickinson, Philips Healthcare, Gentherm, and Stryker are focusing on strategic alliances, product launches, and acquisitions to expand their global reach.

Noteworthy developments include:

• In May 2025, Sweden-based TEQCool AB introduced a patented non-invasive intranasal brain cooling system, offering a novel method for brain metabolism reduction beyond traditional TH applications.

• In January 2024, SourceMark entered a partnership with Gentherm Medical to distribute reusable warming and cooling gel pads in the U.S., reinforcing distribution capabilities and enhancing clinical reach.

• Pluss Advanced Technologies, a major innovator from India, has successfully deployed its MiraCradle system across more than 125 hospitals, providing compelling evidence for the efficacy of low-cost hypothermia solutions.

Key Companies Operating in the Market

• Asahi Kasei Corporation

• Audax Management Company, LLC

• Becton, Dickinson and Company (BD)

• EM-MED Sp. z o.o. Sp. K.

• Gentherm Incorporated

• International Biomedical Ltd.

• Phoenix Medical Systems Pvt. Ltd.

• Shenzhen Comen Medical Instruments Co., Ltd.

• Stryker Corporation

• Terumo Corporation

Outlook for 2025–2032

The therapeutic hypothermia systems market is on a robust growth trajectory, underpinned by rising clinical evidence supporting its use across multiple indications. As healthcare systems globally invest in improving patient outcomes post-cardiac and neurological events, the demand for precise, effective, and affordable cooling systems is poised to rise steadily. Innovations in AI, remote monitoring, and non-invasive technologies will continue to redefine the competitive landscape and make therapeutic hypothermia more accessible across income segments and geographies.